CorMedix stock price triggers Bollinger Bands Narrowing, KDJ Death Cross signal.

Tuesday, Jul 15, 2025 3:01 pm ET1min read

The 15-minute chart for CorMedix is currently exhibiting Bollinger Bands Narrowing, as well as a KDJ Death Cross at 07/15/2025 14:45. This indicates a decrease in the magnitude of stock price fluctuations, and a shift in momentum towards the downside, with potential further decreases in the stock price.

CorMedix Inc. (CRMD), a pharmaceutical and medical device company, has maintained a strong track record of exceeding earnings estimates in its recent quarters. The company's earnings per share (EPS) for the last reported quarter was $0.3, surpassing the Zacks Consensus Estimate of $0.25 by 20.00%. This follows a previous quarter where the company's earnings of $0.22 per share exceeded expectations by 29.41% [1].

CorMedix's ability to consistently beat earnings estimates has driven higher estimates and a positive Zacks Earnings ESP (Expected Surprise Prediction) of +20.00%, indicating analysts' recent bullishness on the company's earnings prospects. This positive Earnings ESP, combined with the stock's Zacks Rank #3 (Hold), suggests a high likelihood of another earnings beat [1].

However, technical indicators are signaling a potential shift in momentum. The 15-minute chart for CorMedix is currently exhibiting Bollinger Bands Narrowing, indicating a decrease in the magnitude of stock price fluctuations. Additionally, a KDJ Death Cross occurred on July 15, 2025, at 14:45, which suggests a shift in momentum towards the downside, potentially leading to further decreases in the stock price [2].

While CorMedix's earnings beat streak is encouraging, investors should remain cautious due to the current technical indicators. It is essential to monitor both earnings releases and technical charts to make informed investment decisions.

References:
[1] https://www.nasdaq.com/articles/can-cormedix-crmd-keep-earnings-surprise-streak-alive
[2] Provided source materials

Comments



Add a public comment...
No comments

No comments yet